Press Room

DDL 2020

Start
Wednesday, December 09, 2020 - 00:00
End
Friday, December 11, 2020 - 00:00
Location: online
Drug Delivery To The Lungs 2020 logo | Hovione

Register for free and access the DDL2020 live virtual event here and visit Hovione’s booth.

Do not miss Hovione's Scientists presentations:

Flash Presentation 

December 11, 2020, 13:45 - 13:55

​​​​​Benchmarking of particle engineering technologies for nasal powder manufacture

Flash Speaker: Patricia Henriques





On-Demand Presentation nr.7

Exploring the potential and practicalities of semi-automation in inhaler testing

Presenters: Raquel Borda D’Agua (Hovione) & Anna Sipitanou (Copley)





On-Demand Presentation nr.15

Spray-dried composite formulation for lung sustained release

Presenter: Beatriz Noriega Fernandes 

 

 

Schedule a meeting today

and connect with one of our Inhalation Experts

 

Take advantage of cutting-edge particle engineering technologies highly skilled responsive staff and state of the art analytical facilities.

 

 

Inhalation high performance APIs particle engineering formulation DPIs pdf | Hovione

 

Everything for Inhalation

 

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026